This inventor holds 1 USPTO granted patent. Top assignee: Riken Corporation. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Tadafumi Kato: Innovator in Mitochondrial Research
Introduction
Tadafumi Kato is a prominent inventor based in Wako, Japan. He has made significant contributions to the field of mitochondrial research, particularly in developing compounds that inhibit mitochondrial permeability transition pore (mPTP) opening. His work aims to address various diseases through innovative therapeutic solutions.
Latest Patents
Tadafumi Kato holds a patent for a novel compound that exhibits mPTP-opening inhibitory activity. The patent, titled "Mitochondrial permeability transition pore (mPTP)-opening inhibitor, novel compound exhibiting mPTP-opening inhibitory activity, and use therefor," focuses on providing a compound with high mPTP-opening inhibitory activity. This invention is crucial for developing effective treatments for various diseases.
Career Highlights
Kato is associated with Riken Corporation, where he has been instrumental in advancing mitochondrial research. His dedication to innovation has led to the development of therapeutic compounds that hold promise for medical applications.
Collaborations
Throughout his career, Tadafumi Kato has collaborated with notable colleagues, including Hirochika Kawakami and Ko Kikuzato. These partnerships have fostered a collaborative environment that enhances research and development in the field.
Conclusion
Tadafumi Kato's contributions to mitochondrial research and his innovative patent demonstrate his commitment to advancing medical science. His work continues to inspire future developments in therapeutic solutions for various diseases.